Piramal Pharma Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Piramal Pharma will hold a meeting of the Board of Directors of the Company on 14 May 2025.

Powered by Capital Market - Live News

This was achieved by creating capacity for Sevoflurane manufacture at the Digwal facility in addition to existing capabilities at the Company?s facility at Bethlehem, Pennsylvania, USA.

This would boost the company?s capability to also tap into Inhalation Anesthesia opportunities in the ROW markets in addition to the USA markets,? Piramal Pharma said in a statement.

Piramal Pharma (PPL) is a part of the Piramal group of companies. The pharmaceutical product portfolio of the company can be categorised into contract development and manufacturing organisations (CDMO), complex hospital generics (critical care), and consumer healthcare (OTC).

The scrip rose 0.89% to currently trade at Rs 227.6 on the BSE.

Powered by Capital Market - Live News

Piramal Pharma Ltd rose 3.8% today to trade at Rs 229.65. The BSE Healthcare index is up 0.47% to quote at 41671.82. The index is up 3.91 % over last one month. Among the other constituents of the index, Kopran Ltd increased 2.86% and Ajanta Pharma Ltd added 2.76% on the day. The BSE Healthcare index went up 22.24 % over last one year compared to the 4.89% surge in benchmark SENSEX.

Piramal Pharma Ltd has added 14.57% over last one month compared to 3.91% gain in BSE Healthcare index and 0.34% rise in the SENSEX. On the BSE, 1.17 lakh shares were traded in the counter so far compared with average daily volumes of 5.79 lakh shares in the past one month. The stock hit a record high of Rs 307.85 on 06 Nov 2024. The stock hit a 52-week low of Rs 117.3 on 26 Mar 2024.

Powered by Capital Market - Live News

This was achieved by creating capacity for Sevoflurane manufacture at the Digwal facility in addition to existing capabilities at the Company?s facility at Bethlehem, Pennsylvania, USA.

This would boost the company?s capability to also tap into Inhalation Anesthesia opportunities in the ROW markets in addition to the USA markets,? Piramal Pharma said in a statement.

Piramal Pharma (PPL) is a part of the Piramal group of companies. The pharmaceutical product portfolio of the company can be categorised into contract development and manufacturing organisations (CDMO), complex hospital generics (critical care), and consumer healthcare (OTC).

The scrip rose 0.89% to currently trade at Rs 227.6 on the BSE.

Powered by Capital Market - Live News

Piramal Pharma Ltd rose 3.8% today to trade at Rs 229.65. The BSE Healthcare index is up 0.47% to quote at 41671.82. The index is up 3.91 % over last one month. Among the other constituents of the index, Kopran Ltd increased 2.86% and Ajanta Pharma Ltd added 2.76% on the day. The BSE Healthcare index went up 22.24 % over last one year compared to the 4.89% surge in benchmark SENSEX.

Piramal Pharma Ltd has added 14.57% over last one month compared to 3.91% gain in BSE Healthcare index and 0.34% rise in the SENSEX. On the BSE, 1.17 lakh shares were traded in the counter so far compared with average daily volumes of 5.79 lakh shares in the past one month. The stock hit a record high of Rs 307.85 on 06 Nov 2024. The stock hit a 52-week low of Rs 117.3 on 26 Mar 2024.

Powered by Capital Market - Live News

In a regulatory filing made after market hours yesterday, the pharmaceutical company stated that the US FDA had conducted a General GMP inspection at its Turbhe facility from 11th February 2025 to 17th February 2025.

On conclusion of the inspection, a Form-483 was issued with 6 observations. “Observations are largely around improvement of procedures and practices and not related to data integrity.

The company is preparing a detailed response to said observations, which will be submitted to agency within stipulated timelines,” Piramal Pharma said in a statement.

Piramal Pharma (PPL) is a part of the Piramal group of companies. The pharmaceutical product portfolio of the company can be categorised into contract development and manufacturing organisations (CDMO), complex hospital generics (critical care), and consumer healthcare (OTC).

Powered by Capital Market - Live News

Piramal Pharma will hold a meeting of the Board of Directors of the Company on 14 May 2025.

Powered by Capital Market - Live News

This was achieved by creating capacity for Sevoflurane manufacture at the Digwal facility in addition to existing capabilities at the Company?s facility at Bethlehem, Pennsylvania, USA.

This would boost the company?s capability to also tap into Inhalation Anesthesia opportunities in the ROW markets in addition to the USA markets,? Piramal Pharma said in a statement.

Piramal Pharma (PPL) is a part of the Piramal group of companies. The pharmaceutical product portfolio of the company can be categorised into contract development and manufacturing organisations (CDMO), complex hospital generics (critical care), and consumer healthcare (OTC).

The scrip rose 0.89% to currently trade at Rs 227.6 on the BSE.

Powered by Capital Market - Live News

Piramal Pharma Ltd rose 3.8% today to trade at Rs 229.65. The BSE Healthcare index is up 0.47% to quote at 41671.82. The index is up 3.91 % over last one month. Among the other constituents of the index, Kopran Ltd increased 2.86% and Ajanta Pharma Ltd added 2.76% on the day. The BSE Healthcare index went up 22.24 % over last one year compared to the 4.89% surge in benchmark SENSEX.

Piramal Pharma Ltd has added 14.57% over last one month compared to 3.91% gain in BSE Healthcare index and 0.34% rise in the SENSEX. On the BSE, 1.17 lakh shares were traded in the counter so far compared with average daily volumes of 5.79 lakh shares in the past one month. The stock hit a record high of Rs 307.85 on 06 Nov 2024. The stock hit a 52-week low of Rs 117.3 on 26 Mar 2024.

Powered by Capital Market - Live News

This was achieved by creating capacity for Sevoflurane manufacture at the Digwal facility in addition to existing capabilities at the Company?s facility at Bethlehem, Pennsylvania, USA.

This would boost the company?s capability to also tap into Inhalation Anesthesia opportunities in the ROW markets in addition to the USA markets,? Piramal Pharma said in a statement.

Piramal Pharma (PPL) is a part of the Piramal group of companies. The pharmaceutical product portfolio of the company can be categorised into contract development and manufacturing organisations (CDMO), complex hospital generics (critical care), and consumer healthcare (OTC).

The scrip rose 0.89% to currently trade at Rs 227.6 on the BSE.

Powered by Capital Market - Live News

Piramal Pharma Ltd rose 3.8% today to trade at Rs 229.65. The BSE Healthcare index is up 0.47% to quote at 41671.82. The index is up 3.91 % over last one month. Among the other constituents of the index, Kopran Ltd increased 2.86% and Ajanta Pharma Ltd added 2.76% on the day. The BSE Healthcare index went up 22.24 % over last one year compared to the 4.89% surge in benchmark SENSEX.

Piramal Pharma Ltd has added 14.57% over last one month compared to 3.91% gain in BSE Healthcare index and 0.34% rise in the SENSEX. On the BSE, 1.17 lakh shares were traded in the counter so far compared with average daily volumes of 5.79 lakh shares in the past one month. The stock hit a record high of Rs 307.85 on 06 Nov 2024. The stock hit a 52-week low of Rs 117.3 on 26 Mar 2024.

Powered by Capital Market - Live News

In a regulatory filing made after market hours yesterday, the pharmaceutical company stated that the US FDA had conducted a General GMP inspection at its Turbhe facility from 11th February 2025 to 17th February 2025.

On conclusion of the inspection, a Form-483 was issued with 6 observations. “Observations are largely around improvement of procedures and practices and not related to data integrity.

The company is preparing a detailed response to said observations, which will be submitted to agency within stipulated timelines,” Piramal Pharma said in a statement.

Piramal Pharma (PPL) is a part of the Piramal group of companies. The pharmaceutical product portfolio of the company can be categorised into contract development and manufacturing organisations (CDMO), complex hospital generics (critical care), and consumer healthcare (OTC).

Powered by Capital Market - Live News